专题报道 |
|
|
|
|
SN-38与索拉非尼联合应用体外抗肝癌效果及其机制 |
徐力, 朱园润, 陈建, 杨晓春, 罗沛华 |
浙江大学药学院, 浙江杭州 310058 |
|
Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism |
XU Li, ZHU Yuan-run, CHEN Jian, YANG Xiao-chun, LUO Pei-hua |
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China |
[1] |
TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
|
[2] |
XIE B, WANG D H, SPECHLER S J. Sorafenib for treatment of hepatocellular carcinoma:a systematic review[J]. Dig Dis Sci, 2012,57(5):1122-1129.
|
[3] |
BRANDI G, BIASCO G, MIRARCHI M G, et al. A phase I study of continuous hepatic arterial infusion of irinotecan in patients with locally advanced hepatocellular carcinoma[J]. Dig Liver Dis, 2011,43(12):1015-1021.
|
[4] |
FONT A, SANCHEZ J M, ROSELL R, et al. Phase I study of weekly CPT-11(irinotecan)/docetaxel in patients with advanced solid tumors[J]. Lung Cancer, 2002,37(2):213-218.
|
[5] |
HOLLEBECQUE A, MALKA D, FERTÉ C, et al. Systemic treatment of advanced hepatocellular carcinoma:from disillusions to new horizons[J]. Eur J Cancer, 2015,51(3):327-339.
|
[6] |
BOIGE V, TAÏEB J, HEBBAR M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma:a multicenter phase II study with dose adjustment according to baseline serum bilirubin level[J]. Eur J Cancer, 2006,42(4):456-459.
|
[7] |
WYLLIE A H. Apoptosis:an overview[J]. Br Med Bull, 1997,53(3):451-465.
|
[8] |
HENGARTNER M O. The biochemistry of apoptosis[J]. Nature, 2000,407(6805):770-776.
|
[9] |
RICCARDI C, NICOLETTI I. Analysis of apoptosis by propidium iodide staining and flow cytometry[J]. Nat Protoc, 2006,1(3):1458-1461.
|
[10] |
NUNEZ R. DNA measurement and cell cycle analysis by flow cytometry[J]. Curr Issues Mol Biol, 2001,3(3):67-70.
|
[11] |
VOGELSTEIN B, LANE D, LEVINE A J. Surfing the p53 network[J]. Nature, 2000,408(6810):307-310.
|
[12] |
EVAN G I, VOUSDEN K H. Proliferation, cell cycle and apoptosis in cancer[J]. Nature, 2001,411(6835):342-348.
|
[13] |
BUNZ F, DUTRIAUX A, LENGAUER C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage[J]. Science, 1998,282(5393):1497-1501.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|